The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16).
 
Kosuke Kawaguchi
No Relationships to Disclose
 
Eiji Suzuki
No Relationships to Disclose
 
Tatsuki R Kataoka
No Relationships to Disclose
 
Masahiro Hirata
No Relationships to Disclose
 
Shinji Ohno
No Relationships to Disclose
 
Hiroko Bando
No Relationships to Disclose
 
Hiroshi Ishiguro
Consulting or Advisory Role - Lilly
Research Funding - Chugai Pharma (Inst)
 
Kenichi Inoue
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Novartis (Inst); Puma Biotechnology (Inst)
 
Naohito Yamamoto
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst)
 
Katsumasa Kuroi
No Relationships to Disclose
 
Satoshi Morita
Honoraria - Chugai Pharma
 
Norikazu Masuda
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
 
Masakazu Toi
Research Funding - Chugai Pharma (Inst); Novartis (Inst)